Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Turn Therapeutics Inc (TTRX)

20 + Investors. Track Smart Money conviction in TTRX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -2
Streak
1Q ▼
Buyers last Q
46%

Smart Money Signals — TTRX

Based on 20 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 1Q
For 1 consecutive quarter, more hedge funds reduced or closed their TTRX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 91% of 0.5Y peak

91% of all-time peak
20 funds currently hold this stock — 91% of the 0.5-year high of 22 funds (reached 2025 Q4). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
🟠

More sellers than buyers — 46% buying

6 buying7 selling
Last quarter: 7 funds reduced or exited vs 6 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
🔄

Mostly new holders — 100% entered in last year

■ 0% conviction (2yr+) ■ 0% medium ■ 100% new
Only 0 funds (0%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
💎

Buying through price weakness — shares -1%, value -20%

Value
-19%
Shares
0%
Last quarter: funds added -1% more shares while total portfolio value only changed -20%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
🌱

Early stage — 100% of holders entered in last year

■ 0% veterans ■ 0% 1-2yr ■ 100% new
Of 20 current holders: 20 (100%) entered in the past year, only 0 (0%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.
✅

Strong quality — 27% AUM from major funds

27% from top-100 AUM funds
7 of 20 holders rank in the top 100 by AUM, accounting for 27% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
5.2
out of 10
Moderate Exit Risk
Exit risk score 5.2/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — TTRX

In 2026 Q1, 6 hedge funds were net buyers of TTRX (3 opened a new position, 3 added to an existing one), while 7 reduced or exited (2 trimmed, 5 sold completely) — a 46% buyer ratio, indicating roughly balanced activity. 27% of total institutional value in TTRX is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: -2 funds (more exits than new entries). Total institutional holders: 20.

Hedge Fund Ownership: TTRX

How many hedge funds hold TTRX — quarterly history vs. share price
Quarterly hedge fund ownership of TTRX vs. share price

Market Analysis: TTRX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: TTRX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Turn Therapeutics Inc (TTRX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much TTRX has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 83d ago
TTRX
+83.4%
XLV
+705.0%

TTRX outperformed XLV by -621.6% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 38d ago
TTRX
+44.9%
XLV
+691.9%

Since the filing became public, TTRX outperformed XLV by -647.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

2 top-rated funds 0 high-conviction
Consensus
2.1
/ 10
breadth
×
Elite
0.0
/ 10
conviction
Hedge Fund Positioning: TTRX
20 + Investors

Track Smart Money conviction in TTRX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 20 22 -9.09%
13F Shares 462K 466K -0.89%
Total Value $1M $2M -19.5%
New Positions 3 22 -19
Increased Positions 3 0 +3
Closed Positions 5 0 +5
Reduced Positions 2 0 +2
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: TTRX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

20 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in TTRX. Verified SEC 13F-HR filings.

QUARTER:
Top 19 TTRX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Wellington Shields & Co., LLC 0.05% 65,732 $210K
2 DDFG, Inc 0.05% 70,534 $226K
3 Tamar Securities, LLC 0.01% 30,000 $96K
4 RVW Wealth, LLC 0.00% 18,000 $58K
5 Hodges Capital Management Inc. 0.00% 10,000 $32K
6 XTX Topco Ltd 0.00% 19,727 $63K
7 Composition Wealth, LLC 0.00% 16,000 $51K
8 Brown Brothers Harriman & Co 0.00% 23,688 $76K
9 Pflug Koory, LLC 0.00% 170 —
10 Millennium Management LLC 0.00% 69,757 $223K
11 HighTower Advisors, LLC 0.00% 19,684 $63K
12 Blue Trust, Inc. 0.00% 1,122 $4K
13 LPL Financial LLC 0.00% 13,300 $43K
14 Vanguard Fiduciary Trust Co 0.00% 12,480 $40K
15 Vanguard Capital Management LLC 0.00% 49,450 $158K
16 Bank of America Corp /de/ 0.00% 14,124 $45K
17 Morgan Stanley 0.00% 10,000 $32K
18 Wells Fargo & Company/Mn 0.00% 1,000 $3K
19 UBS Group AG 0.00% 400 $1K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Turn Therapeutics Inc (TTRX)

What does the Smart Money Trend signal show for TTRX?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their TTRX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for TTRX?

More sellers than buyers — 46% buying: Last quarter: 7 funds reduced or exited vs 6 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for TTRX holders?

Strong quality — 27% AUM from major funds: 7 of 20 holders rank in the top 100 by AUM, accounting for 27% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held TTRX?

Mostly new holders — 100% entered in last year: Only 0 funds (0%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Turn Therapeutics Inc (TTRX) following the 2026 Q1 hedge fund 13F filings?

As of today, TTRX has moved +44.9% since the 2026 Q1 13F filing date (May 15, 2026), compared to +691.9% for the XLV sector ETF — an outperformance of -647.0%. Since the quarter end (March 31, 2026), TTRX has gained +83.4% vs +705.0% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →